Network pharmacology analysis and molecular mechanism of paeoniflorin and its metabolite in prolactinoma cells

被引:0
|
作者
Cao, Min [1 ]
Xu, Lun-shan [1 ]
Huang, Ping [1 ]
Fan, Bin-bin [1 ]
Zhang, Yi-hua [1 ]
机构
[1] Army Med Univ, Daping Hosp, Dept Neurosurg, Chongqing, Peoples R China
关键词
Prolactinoma; Paeoniflorin; Albiflorin; Network pharmacology; MMP9; PITUITARY-ADENOMAS; PATHWAY; MMP-9; MATRIX-METALLOPROTEINASE-9; EXPRESSION; DISORDERS; SECRETION;
D O I
10.1007/s11030-024-10923-8
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Prolactinoma was the most common functional pituitary neuroendocrine tumor tissue type, which was caused by excessive proliferation of pituitary prolactin (PRL) cells. Drug therapy of dopamine receptor agonists was generally considered as the prior treatment for prolactinoma patients. However, there were still prolactinoma patients who were resistant to dopamine agonists. Studies have been reported that paeoniflorin can inhibit the secretion of PRL in prolactinoma cells lacking dopamine D2 receptor (D2R) expression, and paeoniflorin can be metabolized into albiflorin by intestinal flora in rats. The effect of albiflorin on prolactinoma has not been reported yet. In this study, network pharmacology was used to analyze the mechanism of paeoniflorin and its metabolite albiflorin as multi-target therapy for prolactinoma, and the experimental verification was carried out. In order to clarify the complex relationship among paeoniflorin, albiflorin and prolactinoma, we constructed a component-target-disease network, and further constructed interaction network, MMP9, EGFR, FGF2, FGFR1 and LGALS3 were screened as the core targets. Kyoto encyclopedia of genes and genomes (KEGG) analysis showed that paeoniflorin and albiflorin may be involved in various pathways in the treatment of prolactinoma, included relaxin signaling pathway and PI3K-Akt signaling pathway. Molecular docking analysis showed that paeoniflorin and albiflorin had good binding activity with MMP9. Western blotting results showed that paeoniflorin and albiflorin could significantly reduce the expression of MMP9, and ELISA results showed that paeoniflorin and albiflorin could significantly reduce the concentration of PRL in GH3 cells, and the reduce degree of albiflorin was stronger than paeoniflorin at 50 mu M, which indicated that albiflorin might be a potential drug to treat prolactinoma, which can regulate prolactinoma through MMP9 and reduce the concentration of PRL. Our study provided a new therapeutic strategy for prolactinoma.Graphical abstractNetwork pharmacology and experimental verification revealed the anti-prolactinoma mechanism of paeoniflorin and albiflorin.
引用
收藏
页码:1415 / 1425
页数:11
相关论文
共 50 条
  • [1] Study on the Mechanism of Paeoniflorin Against Atherosclerosis Through Network Pharmacology and Molecular Docking
    Zhao, Chengguo
    Ling, Wenpei
    Luo, Chunyu
    Yin, Meifang
    Qin, Shuzhi
    JOURNAL OF BIOBASED MATERIALS AND BIOENERGY, 2020, 14 (04) : 467 - 475
  • [2] Network Pharmacology to Explore the Mechanism of Prunella vulgaris L. Against Prolactinoma
    Meng, Jun-Hua
    Ni, Ping
    Cao, Yu-Ling
    Zhang, Yu
    Wang, Xiong
    Zhang, Hong
    Chen, Yong-Gang
    PHARMACOGNOSY MAGAZINE, 2024, 20 (01) : 127 - 136
  • [3] Inhibition of inflammation by berberine: Molecular mechanism and network pharmacology analysis
    Wang, Kaijun
    Yin, Jie
    Chen, Jiayi
    Ma, Jie
    Si, Hongbin
    Xia, Diqi
    PHYTOMEDICINE, 2024, 128
  • [4] Integrating Network Pharmacology and Transcriptomic Strategies to Explore the Pharmacological Mechanism of Paeoniflorin Exerts Antidepressant Effects
    Su, Lili
    Wang, Zixian
    Guo, Pengli
    He, Zhongmei
    Li, Jianming
    Zhao, Yan
    Zong, Ying
    Chen, Weijia
    Du, Rui
    LETTERS IN DRUG DESIGN & DISCOVERY, 2024, 21 (15) : 3206 - 3220
  • [5] Deciphering the action mechanism of paeoniflorin in suppressing pancreatic cancer: A network pharmacology study and experimental validation
    Cao, Chunhao
    Zhao, Wenting
    Chen, Xianglin
    Shen, Bin
    Wang, Teng
    Wu, Chaoxu
    Rong, Xiaofeng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [6] Dissection of the antitumor mechanism of tetrandrine based on metabolite profiling and network pharmacology
    Liu, Cheng-Jun
    Li, Hong-Xin
    Zhang, Yong-Ming
    Shi, Wei
    Zhang, Feng-Xiang
    RAPID COMMUNICATIONS IN MASS SPECTROMETRY, 2024, 38 (01)
  • [7] Network pharmacology analysis and experimental verification of the antitumor effect and molecular mechanism of isocryptomerin on HepG2 cells
    Cao, Jing-Long
    Li, Shu-Mei
    Tang, Yan-Jun
    Hou, Wen-Shuang
    Wang, An-Qi
    Li, Tian-Zhu
    Jin, Cheng-Hao
    DRUG DEVELOPMENT RESEARCH, 2024, 85 (02)
  • [8] Investigating the molecular mechanism of iguratimod act on SLE using network pharmacology and molecular docking analysis
    Zeng, Huiqiong
    Chen, Shuai
    Lu, Xiaoping
    Yan, Zhenbo
    FRONTIERS IN BIOINFORMATICS, 2022, 2
  • [9] Mechanism of Paeoniflorin on ANIT-Induced Cholestatic Liver Injury Using Integrated Metabolomics and Network Pharmacology
    Chen, Lisheng
    Zhao, Xu
    Wei, Shizhang
    Ma, Xiao
    Liu, Honghong
    Li, Jianyu
    Jing, Manyi
    Wang, Min
    Zhao, Yanling
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [10] An integrated strategy to reveal the potential anti-asthma mechanism of peimine by metabolite profiling, network pharmacology, and molecular docking
    Tian, Xi
    Wei, Jinhuan
    Yang, Mengxin
    Niu, Yukun
    Liu, Minyan
    Du, Yingfeng
    Jin, Yiran
    JOURNAL OF SEPARATION SCIENCE, 2022, 45 (15) : 2819 - 2832